Your browser doesn't support javascript.
loading
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Borthakur, Gautam; Ofran, Yishai; Tallman, Martin S; Foran, James; Uy, Geoffrey L; DiPersio, John F; Showel, Margaret M; Shimoni, Avichai; Nagler, Arnon; Rowe, Jacob M; Altman, Jessica K; Abraham, Michal; Peled, Amnon; Shaw, Stephen; Bohana-Kashtan, Osnat; Sorani, Ella; Pereg, Yaron; Foley-Comer, Adam; Oberkovitz, Galia; Lustig, Tzipi M; Glicko-Kabir, Irit; Aharon, Arnon; Vainstein-Haras, Abi; Kadosh, Shaul E; Samara, Emil; Al-Rawi, Ahmed N; Pemmaraju, Naveen; Bueso-Ramos, Carlos; Cortes, Jorge E; Andreeff, Michael.
Afiliación
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ofran Y; Laboratory of genetic and immunology of Leukemia, Rambam Medical Center, Haifa, Israel.
  • Tallman MS; Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Foran J; Cancer center, Bone Marrow Transplant Program, Hematology, Mayo Clinic, Jacksonville, Florida.
  • Uy GL; Oncology Division Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, St Louis, Missouri.
  • DiPersio JF; Oncology Division Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, St Louis, Missouri.
  • Showel MM; Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Shimoni A; Division of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
  • Nagler A; Division of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Israel.
  • Rowe JM; Shaare Zedek Medical Center, Jerusalem, Israel.
  • Altman JK; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
  • Abraham M; Biokine Therapeutics Ltd, Ness Ziona, Israel.
  • Peled A; Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel.
  • Shaw S; Biokine Therapeutics Ltd, Ness Ziona, Israel.
  • Bohana-Kashtan O; Goldyne Savad Institute of Gene Therapy, Hebrew University Hospital, Jerusalem, Israel.
  • Sorani E; BioLineRx Ltd, Modi'in, Israel.
  • Pereg Y; BioLineRx Ltd, Modi'in, Israel.
  • Foley-Comer A; BioLineRx Ltd, Modi'in, Israel.
  • Oberkovitz G; BioLineRx Ltd, Modi'in, Israel.
  • Lustig TM; BioLineRx Ltd, Modi'in, Israel.
  • Glicko-Kabir I; BioLineRx Ltd, Modi'in, Israel.
  • Aharon A; BioLineRx Ltd, Modi'in, Israel.
  • Vainstein-Haras A; BioLineRx Ltd, Modi'in, Israel.
  • Kadosh SE; BioLineRx Ltd, Modi'in, Israel.
  • Samara E; BioLineRx Ltd, Modi'in, Israel.
  • Al-Rawi AN; StatExcellence, Nesher, Israel.
  • Pemmaraju N; PharmaPolaris International Inc, Washington, District of Columbia.
  • Bueso-Ramos C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortes JE; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 127(8): 1246-1259, 2021 04 15.
Article en En | MEDLINE | ID: mdl-33270904

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores CXCR4 / Citarabina Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Péptidos / Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores CXCR4 / Citarabina Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2021 Tipo del documento: Article